Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Albumins
  • Antineoplastic Combined Chemotherapy Protocols
  • Deoxycytidine
  • Paclitaxel
  • Pancreatic Neoplasms

abstract

  • In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).

publication date

  • January 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4631139

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1304369

PubMed ID

  • 24131140

Additional Document Info

start page

  • 1691

end page

  • 703

volume

  • 369

number

  • 18